Testosterone-Drug Focused Penny Stock Falls On Bankruptcy Fears

Testosterone-Drug Focused Penny Stock Falls On Bankruptcy Fears
  • Clarus Therapeutics Holdings Inc CRXT has implemented a 40% reduction in staff as it evaluates strategic alternatives and terminates certain research and development activities.
  • With $19.2 million in cash & cash equivalents and $40.5 million of senior notes payable, the company is pulling out all the stops to stay afloat.
  • Clarus also decided to combine the positions of chief financial officer and chief administrative officer. As a result, CFO Richard Peterson will leave the company while CAO Steven Bourne picks up his job.
  • The company sells an oral testosterone replacement drug, Jatenzo. 
  • Management believes the existing cash balance and sales will fund current estimated operating expenses (after implementing headcount reduction) and capital expenditure requirements into September 2022.
  • The company noted it might have to stop marketing Jatenzo and file for bankruptcy unless it can restructure its indebtedness and find new capital.
  • Robert Dudley, Clarus president & CEO, blames the moves — even as Jatenzo sales have grown — on the challenging financing environment.
  • Clarus expects severance and related expenses for the layoffs to add up to $1.1 million.
  • Price Action: CRXT shares are down 26.5% at $0.2081 on the last check Friday.

Posted In: BriefsBiotechEarningsNewsPenny StocksHealth CareMoversTrading IdeasGeneral